Investigational drug · Phase 2
Tmod CAR T-cell Therapy
Also called: A2B530, A2B694, A2B543, A2B395
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Tmod CAR T-cell Therapy"
First trial start
2023
Apr 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tmod CAR T-cell Therapy", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- Colorectal Cancer
- Colorectal Adenocarcinoma
- CRC
- Cancer
- Pancreas Cancer
- Non Small Cell Lung Cancer
- Non-Small Cell Squamous Lung Cancer
- NSCLC
- NSCLC, Recurrent
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Tmod CAR T-cell Therapy" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT06051695 · 474 participants (planned) · Start Apr 3, 2024 · Primary completion Jun 2028
Drug: A2B694; A2B543 · For: Solid Tumor, Adult; Colorectal Cancer; NSCLC and 17 more
Sites: Gilbert, Arizona; La Jolla, California; Los Angeles, California · 12 sites in all
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT06682793 · 240 participants (planned) · Start May 22, 2025 · Primary completion Mar 31, 2029
Drug: A2B395 · For: Solid Tumor, Adult; Colorectal Cancer; Non-Small Cell Lung and 14 more
Sites: Gilbert, Arizona; Phoenix, Arizona; La Jolla, California · 13 sites in all
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT05736731 · 160 participants (planned) · Start Apr 28, 2023 · Primary completion Dec 2026
Drug: A2B530 · For: Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer and 13 more
Sites: Gilbert, Arizona; La Jolla, California; Los Angeles, California · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- AK119Phase 22 trials
Akeso · Colorectal Cancer, Solid Tumor, Adult
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.